Results in the real world of Ocrelizumab treatment for primary progressive multiple sclerosis (2024)

Daniels, K., van der Nat, P. B., Frequin, S. T. F. M., van der Wees, P. J., Biesma, D. H., Hoogervorst, E. L. J.(2020).Results in the real world of Ocrelizumab treatment for primary progressive multiple sclerosis.Multiple Sclerose International,,2020, Article 5463451.https://doi.org/10.1155/2020/5463451

Daniels, K;van der Nat, p b;Results in the real world of Ocrelizumab treatment for primary progressive multiple sclerosis.I:Multiple Sclerose International.2020; Vol.2020.

@Article {F687CebB4EBB4069A719488F54706404,

title = "Results in the real world of Ocrelizumab treatment for primary progressive multiple sclerosis",

Abstract = "Background: Recent, Ocrelizumab (Ocrevus {\ Texs registered}) Approved for the processing of primary progressive multiple sclerosis (PPMS) based on data from the clinical oratorio study. Real-World has data about the clinical effectiveness of OcrelizaBabNot yet. Conclusion: Ocrelizumab can stabilize handic app programs in patients with PPMs.

Author = "k Daniels and {van der Nat}, {p b} and frequin, {s t f m} and {van der Wees}, {p j} and bijesma, {d h} and Hoogervorst, {e l j} and {van de Gard},{E M W} ",

Note = "Copyright {\ TextCopyright} 2020 K. Daniels et al."

year = "2020",

doi = "10.1155/2020/5463451",

language = "English",

volume = "2020",

Journal = "Multiple Sclerosis International",

ISSN = "2090-2654",

Publisher = "Hindawi Publishing Corporation",

}

Daniels, K, van der Nat, PB, Frequin, STFM, Van der Wees, PJ, Biesma, DH, Hoogervorst, Elj2020, 'Results in the real world of Ocrelizumab treatment for primary progressive multiple sclerosis',Multiple Sclerose International, Vol.2020, 5463451.https://doi.org/10.1155/2020/5463451

Results in the real world of Ocrelizumab treatment for primary progressive multiple sclerosis./ Daniels, K;van der nat, p b;Frequin, s t f m et al.
I:Multiple Sclerose International, Vol.2020, 5463451, 2020.

Research production:Contribution to the diary›Article›Academic›Peer-review

Ty - day

T1 - Results in the real world of Ocrelizumab - Treatment for primary progressive multiple sclerosis

AU - Daniels, K

Au - van der nat, p b

Au - Hyppigt, S T F M

Au - van der Wees, p j

AU - BIESMA, D H

I - Hougemst, E l

Bij - Van de Guard, E M W

N1 - Copyright © 2020 K. Daniels et al.

PY - 2020

Y1 - 2020

N2 - Background: Ocrelizumab (OCREVUS®) was recently approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the clinical oratory research. Objective: The aim of this study was to provide data on the clinical effectiveness of Ocrelizumabfor patients diagnosis PPMs in a real setting. Methods: We have led a cohort study with one restaurant from all patients with PPMs who started treatment with Ocrelizumab (n = 21) on St.Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) betweenApril 2018 and 31 December 2018. The primary result was pre-docrelizumab handicap exacerbation exacerbation (from 96 weeks before the first Ocrelizumab administration up to 24 weeks after the first Ocrelizumab administration). Results: Disposition frequency of disabilities, although significantly separated(lower) of the degree of handicap in the pre -treatment period (Z = -2.81, p ≤ x.01).The treatment begins. Conclusion: Ocrelizumab can stabilize handic app programs in patients with PPMs.Some patients even showed a clinically relevant improvement in the status of a disability.

AB - Background: Ocrelizumab (OCREVUS®) was recently approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the Oratorio Clinical Experiment. Objective: The aim of this study was to provide data on the clinical effectiveness ofOcrelizumab for patients diagnosis PPMs in a real setting. Methods: We have led a cohort study with one restaurant from all patients with PPMs who started treatment with Ocrelizumab (n = 21) on St.Antonius Hospital (Utrecht/Nieuwegein, the Netherlands)Between April 2018 and 31 December 2018. The primary result was pre-drelizumab handicap exacerbation aggravation (from 96 weeks before the first Ocrelizumab administration up to 24 weeks after the first Ocrelizumab administration). Results: Disposition frequency of handicaps, although significantSeparated (lower) of the degree of disability in the pre -treatment period (Z = -2.81, p ≤ x.01).The treatment begins. Conclusion: Ocrelizumab can stabilize handic app programs in patients with PPMs.Some patients even showed a clinically relevant improvement in the status of a disability.

AA - 10.1155/2020/5463451

Do - 10.1155/2020/5463451

With - Artkl

C2 - 32607256

SN - 2090-2654

VL - 2020

Jo - Multiple Sclerosis International

JF - Multiple Sclerosis International

M1 - 5463451

IS -

Daniels K, van der Nat PB, Frequin STFM, van der Wees PJ, Biesma DH, Hoogervorst Elj et al.Results in the real world of Ocrelizumab treatment for primary progressive multiple sclerosis.Multiple Sclerose International.2020;2020: 5463451.doi: 10.1155/2020/5463451